跳至主要内容
临床试验/CTRI/2024/12/077981
CTRI/2024/12/077981尚未招募不适用

The objective of this study will be to evaluate the sensitization potential of Skin Care formulations on healthy human subjects

Panacea Biotec Pharma Ltd.1 个研究点 分布在 1 个国家目标入组 220 人开始时间: 2024年12月18日

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
220
试验地点
1
主要终点
Sensitization potential

研究概览

简要总结

The objective of this study will be to evaluate the sensitization potential of Skin Care formulations on healthy human subjects

The evaluation is performed using: Dermatological Evaluation: Human Repeat Insult Patch Test Method

Total duration of the study: 40 days following the first application of product.

Kinetics: Induction phase with 21 visits(T0, T1, T2, T3, T4, T5, T6, T7, T8, T9, T10, T11, T12, T13, T14, T15, T16, T17, T18, T19 and T20) then resting phase of 14 days and 5 days of Challenge phase( T21, T22, T23, T24 & T25)

The study is conducted in 3 phases:

1.     Induction Phase

2.     Resting Phase

3.     Challenge Phase

Induction phase is of 21 days and in which 9 repeated applications of patches are carried out which are removed after 24 hours of application and evaluated after 24 hours of patch removal. Resting phase is of 14 days in which no application of any patch is done in order to develop sensitization to the test product. In Challenge phase only one patch is applied which is removed after 24 hours and evaluated after 24 hours 48 hours and 72 hours

Number of volunteers: 220 (110 male+110 female) subjects

研究设计

研究类型
Interventional
分配方式
Na
盲法
Participant Blinded

入排标准

年龄范围
18.00 Year(s) 至 65.00 Year(s)(—)
性别
All

入选标准

  • Female and male Asian Indian subjects.
  • Healthy Human subjects (no infectious and evolutive pathology which could make the subject vulnerable and stop the study, no pathology which could interfere with the study, no symptom in the process of an exploratory checkup)
  • Skin is healthy on the studied anatomic unit (free of eczema, wounds, inflammatory scar….).

排除标准

  • For female: Being pregnant or breastfeeding or having stopped to breastfeed in the past three months
  • Having refused to give his or her assent by not signing the consent form
  • Taking part in another study liable to interfere with this study
  • Being diabetic.
  • Being asthmatic.
  • Following a chronic medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, anti-histamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol).
  • Having cutaneous hypersensitivity (except in the case of studies with evaluation of sensitive skin).
  • Having a diagnosed or highly probable allergy to one or several compounds of the cosmetic products.
  • Having changed his or her cosmetic habits in the 14 days preceding the start of the study on the studied anatomic unit.

结局指标

主要结局

Sensitization potential

时间窗: Baseline, Day 3, Day 5, Day 7, Day 10, Day 12, Day 14, Day 17, Day 19, Day 21, Day 38, Day 39, Day 40

次要结局

未报告次要终点

研究者

发起方
Panacea Biotec Pharma Ltd.
申办方类型
Pharmaceutical industry-Indian
责任方
Principal Investigator
主要研究者

Dr Pooja Yadav

MASCOT-SPINCONTROL India Pvt. Ltd.

研究点 (1)

Loading locations...

相似试验